Identification of BRCA mutation in ovarian cancer is vital because it allows better risk management and there is evidence that carriers may benefit from new treatment modalities, said Professor Woo Yin Ling, consultant gynaecological oncologist at the University of Malaya.
At a symposium during the 25th Congress of the Obstetrical and Gynaecological Society of Malaysia in Kuala Lumpur, Professor Susan Davis discussed the unique implications of women living decades beyond menopause, and how healthcare professionals can best manage menopausal symptoms in the short and long term.
At the 47th Annual Scientific Meeting/Annual General Meeting of the Malaysian Orthopaedic Association, Dr Algis Jovaisas discussed important clinical considerations when it comes to choosing between nonselective nonsteroidal anti-inflammatory drugs (nsNSAIDs) and selective COX-2 inhibitors (coxibs) for the management of acute pain.
The latest research, clinical data and innovations in ophthalmology were presented at the 2017 Annual Meeting of the American Academy of Ophthalmology (AAO) in New Orleans, USA, held on 11−14 November 2017. As in previous years, an international panel of renowned ophthalmologists were supported by Pfizer to attend the meeting and contribute articles to create the Eye on AAO 2017 e-Bulletins. Delivered immediately after each meeting day, and developed with full editorial independence, these e-bulletins feature conference highlights of the latest research, hot topics in ophthalmology and their relevance to the Asia Pacific region.
The e-Bulletins are now collected together and available for download from this page; they are sure to be of significant interest to those seeking the latest advances in ophthalmology.
In this issue of MIMS Surgery Supplement, we bring you clinical updates related to anaesthesia in laparoscopic surgery, and also a symposium highlight on how deep neuromuscular block can improve the surgical environment and patient outcomes in laparoscopic surgery.
Laparoscopy is increasingly used in various surgical settings. While creation of the pneumoperitoneum – or insufflation of carbon dioxide into the peritoneal cavity – is central to laparoscopic surgery, this is associated with several physiological changes that can adversely affect surgical outcomes. At a recent symposium organized by Merck Sharp & Dohme, Dr Rajesh Brijball and Dr David Cavalucci elaborated on how deep neuromuscular block in laparoscopic surgery can improve the surgical environment and patient outcomes.
Available in Europe since 1978, trimetazidine was launched in Malaysia in 1986 as VASTAREL® 20, with the first box of this medication sold in 1987. At that time, this agent was available as three times daily dosing; this was soon followed by the modified-release formulation, ie, VASTAREL® MR®, launched in 2005 to simplify the dosing regimen. By 2007, VASTAREL® MR® had become widely available in public hospitals throughout Malaysia.The efficacy of trimetazidine in coronary artery disease (CAD) is well established – it is a well-tolerated anti-ischaemic agent with no effect on blood pressure or heart rate. It is also recommended by Malaysian and international guidelines for symptomatic relief of angina. In conjunction with the 30th anniversary of VASTAREL®, renowned local and international opinion leaders gathered at a Servier symposium, chaired by Dr Jeyamalar Rajadurai, to reflect on the evolution of CAD management and the contemporary role of trimetazidine.
In this issue of MIMS Anti-Infective Supplement, we bring you clinical updates related to combating infectious diseases, and also a symposium highlight in conjunction with the launch of ceftolozane/tazobactam (Zerbaxa; Merck Sharp & Dohme Sdn Bhd) in Malaysia.
A study finds no evidence that using pharmaceutical aids alone for smoking cessation helps improve the chances of successful quitting despite promising results in previous randomized trials and routine prescription of such drugs to help quit smoking.
Cancer patients at risk for recurrent venous thromboembolism (VTE) are less likely to experience recurrence with rivaroxaban compared with dalteparin, the Select-D trial has shown, ushering in a new standard of care (SoC) for cancer-related VTE.